X
X
Total 393357 Results
| Label | Description | ILX | Version | Created CID | Modified Time | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cranial Thermal Index | MISSING | ILX:0102611 | 5 | scicrunch | 08/28/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Craniata | ILX:0102612 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Craniocerebral Trauma | Traumatic injuries involving the cranium and intracranial structures (i.e., BRAIN; CRANIAL NERVES; MENINGES; and other structures). Injuries may be classified by whether or not the skull is penetrated (i.e., penetrating vs. nonpenetrating) or whether there is an associated hemorrhage (MeSH). | ILX:0102613 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Craniopharyngioma | A benign pituitary-region neoplasm that originates from Rathke's pouch. The two major histologic and clinical subtypes are adamantinous (or classical) craniopharyngioma and papillary craniopharyngioma. The adamantinous form presents in children and adolescents as an expanding cystic lesion in the pituitary region. The cystic cavity is filled with a black viscous substance and histologically the tumor is composed of adamantinomatous epithelium and areas of calcification and necrosis. Papillary craniopharyngiomas occur in adults, and histologically feature a squamous epithelium with papillations (MeSH). | ILX:0102614 | 4 | scicrunch | 08/24/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Craspedodromous | A shape inhering in a bearer by virtue of having secondary branches terminating at the margin. | ILX:0102615 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Cre-recombinase | A tyrosine recombinase enzyme derived from the P1 Bacteriophage. The enzyme uses a topoisomerase I like mechanism to carry out site specific recombination events. The enzyme (38kDa) is a member of the Integrase family of site specific recombinase and it is known to catalyse the site specific recombination event between two DNA recognition sites (loxP sites). Cre recombinase is a widely used tool in the field of molecular biology. The enzyme's unique and specific recombination system is exploited to manipulate genes and chromosomes in a huge range of research, such as gene knock out or knock in studies. The enzyme's ability to operate efficiently in a wide range of cellular environments (including mammals, plants, bacteria, and yeast) enables the Cre-Lox recombination system to be used in a vast number of organisms, making it a particularly useful tool in scientific research (Adapted from Wikipedia: http://en.wikipedia.org/wiki/Cre_recombinase) | ILX:0102616 | 4 | scicrunch | 08/24/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Creatine | An amino acid that occurs in vertebrate tissues and in urine. In muscle tissue, creatine generally occurs as phosphocreatine. Creatine is excreted as creatinine in the urine. (PubChem) Pharmacology: Creatine is a essential, non-proteinaceous amino acid found in all animals and, in some plants. Creatine is synthesized in the kidney, liver and pancreas from L-arginine, glycine and L-methionine. Following its biosynthesis, creatine is transported to the skeletal muscle, heart, brain and other tissues. Most of the creatine is metabolized in these tissues to phosphocreatine (creatine phosphate). Phosphocreatine is a major energy storage form in the body. Supplemental creatine may have an energy-generating action during anaerobic exercise and may also have neuroprotective and cardioprotective actions. Mechanism of action: In the muscles, a fraction of the total creatine binds to phosphate - forming creatine phosphate. The reaction is catalysed by creatine kinase, and the result is phosphocreatine (PCr). Phosphocreatine binds with adenosine diphosphate to convert it back to ATP (adenosine triphosphate), an important cellular energy source. Drug type: Approved. Nutraceutical. Small Molecule. Drug category: Dietary supplement. Micronutrient | ILX:0102617 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Creation Date | Date of print job creation. | ILX:0102618 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Creation Time | Time of print job creation. | ILX:0102619 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Creative Commons Attribution License | License that lets others distribute, remix, tweak, and build upon your work, even commercially, as long as they attribute the work in the manner specified. This is the most accommodating of licenses offered. Recommended for maximum dissemination and use of licensed materials. Notice - For any reuse or distribution, you must make clear to others the license terms of this work. The best way to do this is with a link to the CC BY web page. | ILX:0102620 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Creative Commons Attribution-NoDerivs License | License that allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to you in the manner specified.Notice - For any reuse or distribution, you must make clear to others the license terms of this work. The best way to do this is with a link to the CC BY-ND web page. | ILX:0102621 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Creative Commons Attribution-NonCommercial License | License that lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you in the manner specified and be non-commercial, they don't have to license their derivative works on the same terms. Notice - For any reuse or distribution, you must make clear to others the license terms of this work. The best way to do this is with a link to the CC BY-NC web page. | ILX:0102622 | 4 | scicrunch | 08/24/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Creative Commons Attribution-NonCommercial-NoDerivs License | License that is the most restrictive of the six Creative Commons main licenses, only allowing others to download your works and share them with others as long as they credit you in the manner specified, but they can't change them in any way or use them commercially. Notice - For any reuse or distribution, you must make clear to others the license terms of this work. The best way to do this is with a link to the CC BY-NC-ND web page. | ILX:0102623 | 4 | scicrunch | 08/24/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Creative Commons Attribution-NonCommercial-ShareAlike License | License that lets others remix, tweak, and build upon your work non-commercially, as long as they credit you n the manner specified and license their new creations under the identical terms. Notice - For any reuse or distribution, you must make clear to others the license terms of this work. The best way to do this is with a link to the CC BY-NC-SA web page. | ILX:0102624 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Creative Commons License | One of several public copyright licenses that allow the distribution of copyrighted works. A Creative Commons license is used when an author wants to give people the right to share, use, and even build upon a work that they have created. CC provides an author flexibility (for example, they might choose to allow only non-commercial uses of their own work) and protects the people who use or redistribute an author's work, so they don't have to worry about copyright infringement, as long as they abide by the conditions the author has specified.There are several types of CC licenses. The licenses differ by several combinations that condition the terms of distribution. They were initially released on December 16, 2002 by Creative Commons, a U.S. non-profit corporation founded in 2001. (Wikipedia, http://en.wikipedia.org/wiki/Creative_Commons_license) | ILX:0102626 | 4 | scicrunch | 08/24/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Creative Commons Zero License | Universal tool if you are a holder of copyright or database rights, and you wish to waive all your interests in your work worldwide. Using CC0, you can waive all copyrights and related or neighboring rights that you have over your work, such as your moral rights (to the extent waivable), your publicity or privacy rights, rights you have protecting against unfair competition, and database rights and rights protecting the extraction, dissemination and reuse of data.You cannot waive rights to a work that you do not own unless you have permission from the owner. You may use this tool even if your work is free of copyright in some jurisdictions, if you want to ensure it is free everywhere. Creative Commons does not recommend this tool for works that are already in the public domain worldwide, instead use the Public Domain Mark for such works. | ILX:0102627 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Creator-Version UID | Unique identification of the equipment and version of the software that has created the Raw Data information. The UID allows one to avoid attempting to interpret raw data with an unknown format. | ILX:0102628 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Creeping | Very slow swimming during which only the pectoral fins propel the fish forward; also see coasting/drifting (passive sliding without fin use). | ILX:0102629 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Crescent-shaped | A shape produced when a circular disk has a segment of another circle removed from its edge, so that what remains is a shape enclosed by two circular arcs of different diameters which intersect at two points (usually in such a manner that the enclosed shape does not include the center of the original circle). | ILX:0102630 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Creutzfeldt-Jakob Syndrome | A rare transmissible encephalopathy most prevalent between the ages of 50 and 70 years. Affected individuals may present with sleep disturbances, personality changes, ATAXIA; APHASIA, visual loss, weakness, muscle atrophy, MYOCLONUS, progressive dementia, and death within one year of disease onset. A familial form exhibiting autosomal dominant inheritance and a new variant CJD (potentially associated with ENCEPHALOPATHY, BOVINE SPONGIFORM) have been described. Pathological features include prominent cerebellar and cerebral cortical spongiform degeneration and the presence of PRIONS (MeSH). | ILX:0102631 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
About
Base community for the SciCrunch.org infrastructure
Contact Us
X